

Abstract

Candida albicans has the capability to form biofilms on medical devices which leads to disease that is costly to treat with high mortality rates. However, infections caused by other *Candida* species such as *C. glabrata, C.* parapsilosis, and C. tropicalis have been increasing in frequency. When these pathogens attach to the surface of a medical device, they create a biofilm that is highly resistant to antifungal drugs. Much of this drug resistance is due to the matrix, which essentially creates a barrier preventing drugs from reaching the biofilm producing cells. Proteins and carbohydrates such as, β -1,3-glucan, β -1,6-glucan, and mannan are present in the matrix in high quantities. These components potentially contribute to antifungal resistance of the biofilm and the importance of carbohydrates had been demonstrated in *Candida* species. This study focuses on matrix components of non-albicans species in comparison to the highly studied C. albicans. My hypothesis is that matrix mannan of non *albicans* species are similar to those of Candida albicans and are key to antifungal resistance, just as seen for β -1,3-glucan.¹ To collect sufficient matrix material for analysis, biofilms were grown in roller bottles and matrix was harvested after 48 hours. Matrix components were analyzed with phenol sulfuric assay (for total carbohydrate content), and ELISAs (for mannan, β -1,3- glucan, and β -1,6-glucan). We also investigated the role mannan specifically plays in antifungal resistance of non albicans Candida species. XTT assays were used to quantify biofilms following drug treatment with Fluconazole and a combination of Tunicamycin and Fluconazole. We showed that a decrease in matrix mannan causes an increase in fluconazole susceptibility.

Biofilm Formation



•Yeast adherence to surface



•Mature hyphae; matrix production

Initiation

Initial filamentation



 Dispersion of new yeast cells away from biofilm

Extracellula	r Mat	rix (Com	po	siti	on
Critical carbohydrate	e compor	nent (by	y weigł	nt)		
55% Proteins/Glyco 25% Carbobydrates	proteins	α1,2-bra	nched α1,6	5-mannai	ns (85%)	
15% Lipids		$\stackrel{5}{\sim} M \stackrel{1\alpha6}{\longrightarrow} M \stackrel{1\alpha6}{\longrightarrow} M$	$ \begin{array}{c c} & 1\alpha & 1\alpha \\ & & M \end{array} & M \end{array} \\ \begin{array}{c} 1\alpha \\ 1\alpha \end{array} & \begin{array}{c} 1\alpha \\ 1\alpha \end{array} \end{array} $	⁵ - Μ ^{1α6} - Μ ¹ 2 1α	1α6 Μ 1α6 Ι 2 1α	∦ ^{1α6} → Μ ¹ 2 1α
5% DNA		M 2 1α Μ	M M 2 2 1α 1α M M	Μ 2 1α Μ	1α 1α	ν 2 1α Μ
		G - glucose M - mannose	1α 1α	2 1β Μ	2 1α Μ	
		N A	β1,6-gluca	n (14%)		
	6	G 166 G 166	G <u>166</u> G <u>166</u>	G <u>1β6</u> ₌ G <u>1β</u>	³⁶ - G ^{1β6} - G	<u>1β6</u> _ g ^{1β}
		٦.	β1, <mark>3-gluc</mark> a	n (<1%)		
	_3	G 183 G 183	$G \xrightarrow{1\beta3} G \xrightarrow{1\beta3}$		B ³ G 1β3 G	Zarnowsk

Comparison of Matrix Components and Drug Susceptibility between we sachage **Candida albicans and non albicans Candida Species** Keely R. Redhage^{1,2}, Heather Taff², Hiram Sanchez², David Andes²

Department of Microbiology, Oklahoma State University-Stillwater¹ Department of Medical Microbiology and Immunology, University of Wisconsin-Madison²

Focus



Materials and Methods

Collection of Matrix Material:

An individual colony of selected Candida strain was grown with 30 mL of RPMI + MOPS at 37 °C overnight. All culture was then transferred to 2L bottles in 10 mL increments with 80 mL of RPMI + MOPS. Bottles were placed on a rolling device and incubated at 37 °C for 48 hours with one media change after 24 hours. The biofilm was removed from the bottles via scrapping and washing with 0.1% SDS. Harvested biofilm was sonicated for 20 minutes followed by collection of the cell pellet through centrifugation at 4 °C for 20 minutes. Matrix supernatant was collected then lyophilized and dialyzed. Cultures were diluted in RPMI + MOPS to 10^{6} cells/ml⁻ then grown in a 6 well plate with media changes at 1 and 24 hours. Biofilms were harvested at 48 hours, gently sonicated, and centrifuged to collect matrix suspended in the supernatant. Matrix samples were used for mannan ELISAs and normalized by relative biomass using crystal violet assay.

Carbohydrate Analysis of Extracellular Matrix:

Total carbohydrate matrix components were measured using a phenol sulfuric assay. Mannan concentration was measured using a mannan ELISA. Assays were also run using collected supernatant from six well plates along with bottle grown matrix.

XTT Analysis of Extracellular Matrix:

XTT was used to quantify biofilm viability after treatment with flucanozole, or a combination of fluconazole and tunicamycin. Cultures were diluted to 10⁶ cells/mL⁻ in 100 µL of RPMI + MOPS and then seeded on a 96 well plate for 6 hours to allow biofilm growth. After 6 hours media was gently removed via pipitte and washed with 100 µL of 1x PBS. Biofilms were dosed with 90 µL of varying concentrations of fluconazole (1000-125 µg/mL) and tunicamycin (4-0 µg/mL) followed by addition of 90 μ L RPMI + MOPS.. Plates were incubated for 24 hours and then washed with 100 μ L of 1x PBS. Plates were then read with colorimetric XTT assay by treatment with 90µl XTT (0.75 mg/mL concentration) and 10µl PMS (0.32 mg/mL concentration) in a dark room. Plates were incubated for 30 minutes, in the dark, at 37 °C and then read at OD 492 using a microtiter plate reader².



ug/ml fluconazole concentration

yrene plate for 6 hours. Media was then removed and exchanged with either fluconazole, tunicamycin or a combination of both. XTT was used to quantify biofilms at 48 hours and read at OD 492. Data shown is 500

Results



Biofilm was grown in 2L roller bottles according to methods as described above. Biofilm was harvested and purified matrix was analyzed through an indirect mannan ELISA. Collected data was normalized with respect to mg of matrix for the given sample.



Biofilm was grown in six well plates according to methods as described above. Biofilm was harvested and matrix was analyzed through an indirect mannan ELISA. Collected data was normalized by relative biomass using crystal violet assay

- species
- Flucanazole
- susceptibility for *C. parapsilosis*

Conclusions/Future Directions

of Candida albicans non *albicans* species (Figure 1)

Acknowledgements

I would like to extend my gratitude to the entire Andes lab for their help this summer, without you this project would not have been possible. I would especially like to thank Heather Taff for her patience and guidance while completing my project. Thank you Dr. Andes for allowing me to work in your lab and my program director, Dr. Roll, for this wonderful opportunity. I am extremely grateful to my family for their love and support in all my academic endeavors, thank you for always believing in me Funding provided by NSF

References

Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H., Andes D. Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother. 2013 Apr;57(4):1918-20. Nett JE, Cain MT, Crawford K, Andes DR. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J Clin Microbiol. 2011 Apr;49(4):1426-33.



Roller Bottle Mannan ELISA

• Carbohydrates were found in C. glabrata, C. parapsilosis, and C. tropicalis • Significant amounts of mannan were present in all tested non albicans Candida

• The non albicans Candida strains of C. glabrata, C. parapsilosis, and C. tropicalis all showed increased susceptibility with the addition of Tunicamycin to

• Addition of Tunicamycin to Fluconazole did not significantly increase the

•Amount of carbohydrates found in non albicans Candida species is similar to that

•*C. parapsilosis* produced higher levels of matrix per cell than *C. albicans* and other

•C. parapsilosis has less relative matrix mannan and this could explain the inability of tunicamycin to affect drug susceptibility as shown in figure 2.

•Future studies would be an analysis of other extracellular matrix components